Applied Therapeutics ($APLT) Investor Settlement
Applied Therapeutics ($APLT) has reached a settlement with investors over claims that it misled them about its lead drug candidate by hiding dosing errors and missing trial data, which ultimately led to a failed FDA review.
$APLT investors filed a lawsuit against Applied Therapeutics for misleading them about clinical trial data and the regulatory approval process for its lead drug.
On November 27, 2024, Applied Therapeutics revealed that the FDA had issued a Complete Response Letter. Following this news, $APLT stock dropped over 80%.
$APLT investors can join this case to be notified about potential recovery.
Case Details:
Between January 3, 2024, and December 2, 2024, Applied Therapeutics made several optimistic statements about the clinical trial data and regulatory progress for Govorestat, its drug candidate for the treatment of galactosemia.
On February 15, 2024, the company announced positive results from its Phase III trial, noting significant improvements in patient outcomes and key biomarkers.
However, on November 27, 2024, the FDA issued a Complete Response Letter, pointing out serious deficiencies in the New Drug Application for Govorestat, including incomplete data and protocol inconsistencies.
On December 2, 2024, Applied Therapeutics received a warning letter from the FDA for not adequately addressing past trial issues. This raised concerns about the gap between the company’s public claims and the reality of its clinical data and regulatory compliance.
Following these announcements, $APLT plummeted by over 80%.
Based on these events, $APLT investors filed a lawsuit against Applied Therapeutics, claiming the company:
It misled investors about the quality of its clinical trial data and regulatory readiness.
It failed to disclose deficiencies in its clinical practices, including trial data capture and protocol errors.
Investors believe Applied Therapeutics misrepresented its clinical trial results and regulatory progress for Govorestat.
Frequently Asked Questions
All persons and entities that purchased or otherwise acquired the publicly traded common stock of Applied Therapeutics ($APLT) on a U.S.-based exchange between January 3, 2024, and December 2, 2024, inclusive, and were damaged thereby.
No, if you have purchased securities within the class period, you are eligible to participate.
You can participate in the settlement and retain (or sell) your securities.
The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
The final payout amount depends on your specific trades and the number of investors participating in the settlement.
If 100% of investors file their claims - the average payout will be $0.48 per share. Although typically only 25% of investors file claims, in this case, the average recovery will be $1.92 per share.
If you're eligible, you can file your claim directly from this case page by clicking the "Collect Payout" button.
More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed — or file manually for this case.
11th.com is an investor recovery company that helps investors track and collect securities class action settlements. We will:
1. Prepare documents for your payout.
2. Audit the claim and make sure you get the maximum possible payout.
3. File a claim with the settlement administration.
4. Correspond with the settlement administration to resolve emerging issues.
5. Deliver payout directly to your brokerage account.
There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.